ReviewFrontiers in medicine2022
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Studies on allergic diseases and B cells in the past 20 years: a bibliometric analysis via CiteSpace and VOSviewer.Frontiers in immunology · 2026Pooled it
- Assessing the performance of artificial intelligence models in evaluating inflammatory skin disease severity: a systematic review and meta-analysis.The British journal of dermatology · 2025Pooled it
- Molecular and functional changes in neutrophilic granulocytes induced by nicotine: a systematic review and critical evaluation.Frontiers in immunology · 2023Pooled it
- Serum Biomarkers in Bullous Pemphigoid: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.Nature communications · 2024Trial
- CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.Molecular therapy. Advances · 2026Article
- Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Observational
- Pharmaceutical Market Analysis of Topical Semi-Solid Dosage Forms for Skin Disorders in Kazakhstan.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- The Relative Frequency of Oral Lichen Planus and Oral Lichenoid Lesions in a New Zealand Population Diagnosed at a Specialist Reference Centre.Clinical and experimental dental research · 2026Article
- When AI and Experts Agree on Error: Intrinsic Ambiguity in Dermatoscopic Images.Journal of imaging · 2026Article
- T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets.Aging cell · 2026Review
- Artificial intelligence-enabled precision medicine for inflammatory skin diseases.The Journal of investigative dermatology · 2026Review
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Polymeric Nanogels for Skin Applications.Gels (Basel, Switzerland) · 2026Review
- Advances in Bioprinting to Model Immune-Mediated Skin Diseases.Advanced healthcare materials · 2026Review
- Epigenetic Therapies for Inflammatory and Immune-Mediated Skin Diseases.Biomedicines · 2026Review
- Interdisciplinarity traditional Chinese medicine microneedles in skin disease treatment: Recent advances and challenges.Bioactive materials · 2026Review
- Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications.Pharmaceutics · 2025Review
- Autoimmune Skin Diseases in the Era of COVID-19: Pathophysiological Insights and Clinical Implications.Microorganisms · 2025Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 13 institutions in 4 countries.
Funding
Abstract
An estimated 20-25% of the population is affected by chronic, non-communicable inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors. Autoimmunity is another important cause of chronic skin inflammation. The autoimmune response may be mainly T cell driven, such as in alopecia areata or vitiligo, or B cell driven in chronic spontaneous urticaria, pemphigus and pemphigoid diseases. Rare causes of chronic skin inflammation are autoinflammatory diseases, or rheumatic diseases, such as cutaneous lupus erythematosus or dermatomyositis. Whilst we have seen a significant improvement in diagnosis and treatment, several challenges remain. Especially for rarer causes of chronic skin inflammation, early diagnosis is often missed because of low awareness and lack of diagnostics. Systemic immunosuppression is the treatment of choice for almost all of these diseases. Adverse events due to immunosuppression, insufficient therapeutic responses and relapses remain a challenge. For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed. Given the encouraging developments during the past years, we envision that many of these challenges in the diagnosis and treatment of chronic inflammatory skin diseases will be thoroughly addressed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.